Hepatocellular carcinoma: The point of view of the hepatitis B virus

Carcinogenesis

Volumn 32, Issue 8, 2011, Pages 1122-1132

  Pollicino, Teresa ^a   Saitta, Carlo ^a   Raimondo, Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYCLIN A; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; HEPATITIS B VACCINE; HEPSIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEMBRANE PROTEIN; MESSENGER RNA; NUCLEOCAPSID PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; RETINOIC ACID RECEPTOR BETA; RNA POLYMERASE II; SURVIVIN; TATA BINDING PROTEIN; UVOMORULIN; VASCULOTROPIN; VIRUS DNA; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; CANCER INCIDENCE; CANCER RISK; CELL CYCLE PROGRESSION; CELL IMMORTALIZATION; CELL PROLIFERATION; CHROMOSOME DELETION; CHROMOSOME LOSS; DISEASE COURSE; DNA DAMAGE; DNA INTEGRATION; DNA VIRUS; FOLLOW UP; GENE EXPRESSION; GENE SILENCING; GENOMIC INSTABILITY; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNODETECTION; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; NONHUMAN; OBSERVATIONAL STUDY; ONCOGENE H RAS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; UPREGULATION; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS CELL TRANSFORMATION; VIRUS DETECTION; VIRUS DNA CELL DNA INTERACTION; VIRUS ENVELOPE; VIRUS GENE; VIRUS NUCLEOCAPSID; VIRUS REPLICATION; VIRUS STRAIN;

EID: 79961179769     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr108     Document Type: Review

References (264)

1. Prates,D.M. et al. (1965) A cancer survey in Lourenco Marques, Portugese East Africa. J. Natl Cancer Inst., 35, 729-757.
2. Szmuness,W. (1978) Hepatocellular carcinoma and the hepatitis B virus. Evidence for a causal association. Prog. Med. Virol., 24, 40-69.
3. Kew,M.C. (1981) The hepatitis B virus and hepatocellular carcinoma. Semin. Liver Dis., 1, 59-67.
4. Hsu,H.C. et al. (1987) Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J. Hepatol., 5, 260-267.
5. Parkin,D.M. et al. (1993) Estimates of the worldwide incidence of the 18 major cancers in 1985. Int. J. Cancer, 54, 1-13.
6. Hilleman,M.R. (2001) Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine, 19, 1837-1848.
7. Parkin,D.M. et al. (2001) Cancer burden in the year 2000. The global picture. Eur. J. Cancer, 37, S4-S66.
8. Shibuya,K. et al. (2002) Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer, 2, 37.
9. Block,T.M. et al. (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene, 22, 5093-5107.
10. Lok,A.S. (2004) Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology, 127, S303-S309.
11. Cougot,D. et al. (2005) HBV induced carcinogenesis. J. Clin. Virol., 34, S75-S78.
12. Park,N.H. et al. (2006) Chronic hepatitis B in hepatocarcinogenesis. Postgrad. Med. J., 82, 507-515.
13. Lupberger,J. et al. (2007) Hepatitis B virus-induced oncogenesis. World J. Gastroenterol., 13, 74-81.
14. Chang,M.H. (2009) Cancer prevention by vaccination against hepatitis B. Recent Results Cancer Res., 181, 85-94.
15. Hassan,M.M. et al. (2002) Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology, 36, 1206-1213.
16. Kew,M.C. (2003) Synergistic interaction between aflatoxin B1 and hepatitis B virus in hepatocarcinogenesis. Liver Int., 23, 405-409.
17. Velazquez,R.F. et al. (2003) Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology, 37, 520-527.
18. Moradpour,D. et al. (2005) Pathogenesis of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol., 17, 477-483.
19. Chen,C.L. et al. (2008) Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology, 135, 111-121.
20. Raimondo,G. et al. (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol., 49, 652-657.
21. Summers,J. et al. (1978) A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc. Natl Acad. Sci., 75, 4533-4537.
22. Marion,P.L. et al. (1980) A virus in Beechey ground squirrels that is related to hepatitis B virus of humans. Proc. Natl Acad. Sci., 77, 2941-2945.
23. Tennant,B.C. et al. (1991) Hepatocellular carcinoma in Richardson's ground squirrels (Spermophilus richardsonii): evidence for association with hepatitis B-like virus infection. Hepatology, 13, 1215-1221.
24. Testut,P. et al. (1996) A new hepadnavirus endemic in arctic ground squirrels in Alaska. J. Virol., 70, 4210-4219.
25. Seeger,C. et al. (2000) Hepatitis B virus biology. Microbiol. Mol. Biol. Rev., 64, 51-68.
26. Ganem,D. et al. (2004) Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med., 350, 1118-1129.
27. Ganem,D. et al. (1994) Hepatitis B virus reverse transcriptase and its many roles in hepadnaviral genomic replication. Infect. Agents Dis., 3, 85-93.
28. Seeger,C. et al. (1996) Replication of the hepatitis virus genome. In DePamphilis,M.L. (ed) DNA Replication in Eukaryotic Cells. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 815-831.
29. Brechot,C. et al. (1980) Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature, 286, 533-535.
30. Paterlini-Brechot,P. et al. (2003) Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene, 22, 3911-3916.
31. Murakami,Y. et al. (2005) Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut, 54, 1162-1168.
32. Chemin,I. et al. (2009) Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett., 286, 52-59.
33. Kay,A. et al. (2007) Hepatitis B virus genetic variability and evolution. Virus Res., 127, 164-176.
34. Kidd-Ljunggren,K. et al. (2002) Genetic variability in hepatitis B viruses. J. Gen. Virol., 83, 1267-1280.
35. Pujol,F.H. et al. (2009) Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. Cancer Lett., 286, 80-88.
36. Chan,H.L. et al. (2006) Hepatocellular carcinoma and hepatitis B virus. Semin. Liver Dis., 26, 153-161.
37. Llovet,J.M. et al. (2008) Hepatitis B virus genotype and mutants: risk factors for hepatocellular carcinoma. J. Natl Cancer Inst., 100, 1121-1123.
38. Chu,C.J. et al. (2002) Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology, 122, 1756-1762.
39. Chan,H.L. et al. (2003) Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J. Clin. Microbiol., 41, 1277-1279.
40. Fujie,H. et al. (2001) Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology, 120, 1564-1565.
41. Kao,J.H. et al. (2003) Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology, 124, 327-334.
42. Chan,H.L. et al. (2004) Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut, 53, 1494-1498.
43. Yu,M.W. et al. (2005) Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl Cancer Inst., 97, 265-272.
44. Sumi,H. et al. (2003) Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology, 37, 19-26.
45. Yuen,M.F. et al. (2003) Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology, 37, 562-567.
46. Kao,J.H. et al. (2000) Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology, 118, 554-559.
47. Pontisso,P. et al. (1984) Detection of hepatitis B virus DNA in mononuclear blood cells. Br. Med. J., 288, 1563-1566.
48. Raimondo,G. et al. (1988) Interrupted replication of hepatitis B virus in liver tissue of HBsAg carriers with hepatocellular carcinoma. Virology, 166, 103-112.
49. Clementi,M. et al. (1993) Hepatitis B virus preC mutants in human hepatocellular carcinoma tissues. Res. Virol., 144, 297-301.
50. Minami,M. et al. (1996) Precore/core mutations of hepatitis B virus in hepatocellular carcinomas developed on noncirrhotic livers. Gastroenterology, 111, 691-700.
51. Fan,Y.F. et al. (2000) Identification of a pre-S2 mutant in hepatocytes expressing a novel marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection. J. Gastroenterol. Hepatol., 15, 519-528.
52. Tu,H. et al. (2001) Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res., 61, 7803-7810.
53. Oon,C.J. et al. (2002) Molecular characterization of hepatitis B virus surface antigen mutants in Singapore patients with hepatocellular carcinoma and hepatitis B virus carriers negative for HBsAg but positive for anti-HBs and anti-HBc. J. Gastroenterol. Hepatol., 17, S491-S496.
54. Iavarone,M. et al. (2003) Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection. J. Hepatol., 39, 253-261.
55. Kuang,S.Y. et al. (2004) Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc. Natl Acad. Sci. USA, 101, 3575-3580.
56. Buckwold,V.E. et al. (1996) Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol., 70, 5845-5851.
57. Moriyama,K. et al. (1996) Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigenseronegative persistent infections. Virology, 226, 269-280.
58. Buckwold,V.E. et al. (1997) Effects of a frequent double-nucleotide basal core promoter mutation and its putative single-nucleotide precursor mutations on hepatitis B virus gene expression and replication. J. Gen. Virol., 78, 2055-2065.
59. Moriyama,K. (1997) Reduced antigen production by hepatitis B virus harbouring nucleotide deletions in the overlapping X gene and precorecore promoter. J. Gen. Virol., 78, 1479-1486.
60. Scaglioni,P.P. et al. (1997) Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology, 233, 374-381.
61. Parekh,S. et al. (2003) Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J. Virol., 77, 6601-6612.
62. Jammeh,S. et al. (2008) Effect of basal core promoter and pre-core mutations on hepatitis B virus replication. J. Gen. Virol., 89, 901-909.
63. Kurosaki,M. et al. (1996) Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B. J. Med. Virol., 49, 115-123.
64. Sterneck,M. et al. (1998) Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology, 28, 1390-1397.
65. Lindh,M. et al. (1999) Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J. Infect. Dis., 179, 775-782.
66. Chan,H.L. et al. (2000) Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology, 31, 763-768.
67. Chan,H.L. et al. (2002) Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am. J. Gastroenterol., 97, 406-412.
68. Sung,J.J. et al. (2002) Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J. Viral. Hepat., 9, 229-234.
69. Okamoto,H. et al. (1994) Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol., 68, 8102-8110.
70. Kidd-Ljunggren,K. et al. (1997) Hepatitis B virus X gene 1751-1764 mutations: implications for HBeAg status and disease. J. Gen. Virol., 78, 1469-1478.
71. Lindh,M. et al. (1998) Mutation of nucleotide 1762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers. J. Med. Virol., 55, 185-190.
72. Chan,H.L.Y. et al. (1999) Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology, 29, 976-984.
73. Loncarević,I.F. et al. (1990) Replication of hepatitis B virus in a hepatocellular carcinoma. Virology, 174, 158-168.
74. Hsia,C.C. et al. (1996) Hot-spot mutations in hepatitis B virus X gene in hepatocellular carcinoma. Lancet, 348, 625-626.
75. Fang,Z.L. et al. (1998) HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China. J. Med. Virol., 56, 18-24.
76. Baptista,M. et al. (1999) High prevalence of 1762T, 1764A mutations in the basic core promoter of hepatitis B virus isolated from Black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology, 29, 946-953.
77. Liu,S. et al. (2009) Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J. Natl Cancer Inst., 101, 1066-1082.
78. Brechot,C. (2004) Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology, 127, S56-S61.
79. Kremsdorf,D. et al. (2006) Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene, 25, 3823-3833.
80. Sirma,H. et al. (1999) Hepatitis B virus X mutants present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene, 18, 4848-4859.
81. Liu,X. et al. (2008) Mutations in the C-terminus of the X protein of hepatitis B virus regulate Wnt-5a expression in hepatoma Huh7 cells: cDNA microarray and proteomic analyses. Carcinogenesis, 29, 1207-1214.
82. Chisari,F.V. et al. (1989) Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell, 59, 1145-1156.
83. Hagen,T.M. et al. (1994) Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc. Natl Acad. Sci. USA, 91, 12808-12812.
84. Huang,S.N. et al. (1995) Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology, 21, 620-626.
85. Xu,Z. et al. (1997) Activation of hepatitis B virus S promoter by the viral large surface protein via induction of stress in the endoplasmic reticulum. J. Virol., 71, 7387-7392.
86. Hildt,E. et al. (1998) The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Recent Results Cancer Res., 154, 315-329.
87. Hildt,E. et al. (2002) The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J., 21, 525-535.
88. Tai,P.C. et al. (2002) Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants. Virology, 292, 44-58.
89. Hsieh,Y.H. et al. (2004) Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis, 25, 2023-2032.
90. Pagano,J.S. et al. (2004) Infectious agents and cancer: criteria for a causal relation. Semin. Cancer Biol., 14, 453-471.
91. Wang,H.C. et al. (2005) Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. Hepatology, 41, 761-770.
92. Huang,Z.M. et al. (1993) Dysregulated surface gene expression from disrupted hepatitis B virus genomes. J. Virol., 67, 7032-7040.
93. Xu,Z. et al. (1996) Intracellular retention of surface protein by a hepatitis B virus mutant that releases virion particles. J. Virol., 70, 133-140.
94. Hsieh,Y.H. et al. (2007) Hepatitis B virus pre-S2 mutant surface antigen induces degradation of cyclin-dependent kinase inhibitor p27Kip1 through c-Jun activation domain-binding protein 1. Mol. Cancer Res., 5, 1063-1072.
95. Wang,H.C. et al. (2006) Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci., 97, 683-688.
96. Chen,B.F. et al. (2006) High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology, 130, 1153-1168.
97. Chen,C.H. et al. (2007) Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology, 133, 1466-1474.
98. Chen,C.H. et al. (2008) Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J. Infect. Dis., 198, 1634-1642.
99. Liu,S. et al. (2009) Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J. Natl Cancer Inst., 101, 1066-1082.
100. Chen,C.J. et al. (2009) Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology, 49, S72-S84.
101. Iloeje,U.H. et al. (2006) Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 130, 678-686.
102. Chen,C.J. et al. (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA, 295, 65-73.
103. Yang,H.I. et al. (2002) Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N. Engl. J. Med., 347, 168-174.
104. De Franchis,R. et al. (1993) The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med., 118, 191-194.
105. Villeneuve,J.P. et al. (1994) A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology, 106, 1000-1005.
106. Ikeda,K. et al. (2003) Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients. Intervirology, 46, 96-104.
107. Lin,S.M. et al. (1999) Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology, 29, 971-975.
108. van Zonneveld,M. et al. (2004) Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology, 39, 804-810.
109. Liaw,Y.F. et al. (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med., 351, 1521-1531.
110. Shafritz,D.A. et al. (1981) Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellularcarcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N. Engl. J. Med., 305, 1067-1073.
111. Bréchot,C. et al. (1981) ans Tiollais, P. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc. Natl Acad. Sci. USA, 78, 3906-3910.
112. Paterlini,P. et al. (1990) Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N. Engl. J. Med., 323, 80-85.
113. Sheu,J.C. et al. (1992) Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology, 103, 1322-1327.
114. Paterlini,P. et al. (1993) Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology, 17, 20-29.
115. Paterlini,P. et al. (1995) Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology, 21, 313-321.
116. Yu,M.C. et al. (1997) Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology, 25, 226-228.
117. Kubo,S. et al. (1998) Development of hepatocellular carcinoma in patients with HCV infection, with or without past HBV infection, and relationship to age at the time of transfusion. Vox Sang., 74, 129.
118. Huo,T.I. et al. (1998) Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology, 28, 231-236.
119. Koike,K. et al. (1998) Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J. Med. Virol., 54, 249-255.
120. Yotsuyanagi,H. et al. (2004) Role of hepatitis B virus in hepatocarcinogenesis in alcoholics. Alcohol. Clin. Exp. Res., 28, S181-S185.
121. Pollicino,T. et al. (2004) Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology, 126, 102-110.
122. Donato,F. et al. (2006) Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence. Oncogene, 25, 3756-3770.
123. Korba,B.E. et al. (1989) Hepatocellular carcinoma in woodchuck hepatitis virusinfected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology, 9, 461-470.
124. Marion,P.I. (1991) In: McLachlan,A. (ed) Molecular Biology of Hepatitis B Virus. CRC Press, Boca Raton, FL, pp. 39-51.
125. Raimondo,G. et al. (2007) Occult hepatitis B virus infection. J. Hepatol., 46, 160-170.
126. Squadrito,G. et al. (2006) Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer, 106, 1326-1330.
127. Torbenson,M. et al. (2002) Occult hepatitis B. Lancet Infect. Dis., 2, 479-486.
128. Balkwill,F. et al. (2001) Inflammation and cancer: back to Virchow? Lancet, 357, 539-545.
129. Chisari,F.V. et al. (1985) A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science, 230, 1157-1160.
130. Chisari,F.V. (2000) Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am. J. Pathol., 156, 1117-1132.
131. Singh,M. et al. (2003) Transgenic mouse models of hepatitis B virusassociated hepatocellular carcinoma. Rev. Med. Virol., 13, 243-253.
132. Ferrari,C. et al. (2003) Immunopathogenesis of hepatitis B. J. Hepatol., 39, S36-S42.
133. Visvanathan,K. et al. (2006) Immunopathogenesis: role of innate and adaptive immune responses. Semin. Liver Dis., 26, 104-115.
134. Bosch,F.X. et al. (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology, 127, S5-S16.
135. El-Serag,H.B. et al. (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132, 2557-2576.
136. Ghebranious,N. et al. (1998) Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice. Hepatology, 27, 383-391.
137. Maeda,S. et al. (2005) IKKbeta couples hepatocyte death to cytokinedriven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell, 121, 977-990.
138. Wang,S.H. et al. (2009) Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology, 50, 1392-1402.
139. Fwu,C.W. et al. (2009) Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J. Natl Cancer Inst., 101, 1019-1027.
140. Schirmacher,P. et al. (1992) Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth. Cancer Res., 52, 2549-2556.
141. Yang,D. et al. (1993) Coordinate expression of N-myc 2 and insulin-like growth factor II in precancerous altered hepatic foci in woodchuck hepatitis virus carriers. Cancer Res., 53, 2020-2027.
142. Toshkov,I. et al. (1994) Hepatic preneoplasia in hepatitis B virus transgenic mice. Hepatology, 20, 1162-1172.
143. Bannasch,P. et al. (1997) Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J. Bioenerg. Biomembr., 29, 303-313.
144. Scharf,J.G. et al. (1998) Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis, 19, 2121-2128.
145. Radaeva,S. et al. (2000) Hepadnaviral hepatocarcinogenesis: in situ visualization of viral antigens, cytoplasmic compartmentation, enzymic patterns, and cellular proliferation in preneoplastic hepatocellular lineages in woodchucks. J. Hepatol., 33, 580-600.
146. Scharf,J.G. et al. (2001) The IGF axis and hepatocarcinogenesis. Mol. Pathol., 54, 138-144.
147. Longato,L. et al. (2009) Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology, 49, 1935-1943.
148. Bréchot,C. et al. (2000) Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin. Cancer Biol., 10, 211-231.
149. Minami,M. et al. (2005) Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis. Oncogene, 24, 4340-4348.
150. Hsu,T. et al. (1988) Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell, 55, 627-635.
151. Etiemble,J. et al. (1989) Fused transcripts of c-myc and a new cellular locus, hcr in a primary liver tumor. Oncogene, 4, 51-57.
152. Möröy,T. et al. (1989) Structure and expression of hcr, a locus rearranged with c-myc in a woodchuck hepatocellular carcinoma. Oncogene, 4, 59-65.
153. Fourel,G. et al. (1990) Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature, 347, 294-298.
154. Hansen,L.J. et al. (1993) Differential activation of myc gene family members in hepatic carcinogenesis by closely related hepatitis B viruses. Mol. Cell. Biol., 13, 659-667.
155. Matsubara,K. et al. (1990) Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol. Biol. Med., 7, 243-260.
156. Cha,C. et al. (2005) Molecular mechanisms in hepatocellular carcinoma development. Best Pract. Res. Clin. Gastroenterol., 19, 25-37.
157. Feitelson,M.A. et al. (2007) Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. Cancer Lett., 252, 157-170.
158. Arbuthnot,P. et al. (2001) Hepatitis B virus and hepatocellular carcinoma. Int. J. Exp. Pathol., 82, 77-100.
159. Bonilla Guerrero,R. et al. (2005) The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J. Hepatol., 42, 760-777.
160. Wang,Y. et al. (2004) Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis. Oncogene, 23, 142-148.
161. Schlüter,V. et al. (1994) Integrated hepatitis B virus X and 3' truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene, 9, 3335-3344.
162. Yen,T.S. (1996) Hepadnaviral X protein: review of recent progress. J. Biomed. Sci., 3, 20-30.
163. Yoo,Y.D. et al. (1996) Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis. J. Clin. Invest., 97, 388-395.
164. Luber,B. et al. (1996) Hepatoma-derived integrated HBV DNA causes multi-stage transformation in vitro. Oncogene, 12, 1597-1608.
165. Lara-Pezzi,E. et al. (1998) The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology, 28, 1013-1021.
166. Slagle,B.L. et al. (1991) Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in virus-positive hepatocellular carcinomas. Cancer Res., 51, 49-54.
167. Pineau,P. et al. (1998) Extensive analysis of duplicated-inverted hepatitis B virus integrations in human hepatocellular carcinoma. J. Gen. Virol., 79, 591-600.
168. Thorgeirsson,S.S. et al. (2002) Molecular pathogenesis of human hepatocellular carcinoma. Nat. Genet., 31, 339-346.
169. Tamori,A. et al. (2005) Alteration of gene expression in human hepatocellular carcinoma with integrated hepatitis B virus DNA. Clin. Cancer Res., 11, 5821-5826.
170. Wang,J. et al. (1990) Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature, 343, 555-557.
171. Wang,J. et al. (1992) Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene, 7, 1653-1656.
172. Berasain,C. et al. (1998) Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon hepatitis B virus genome insertion. Oncogene, 16, 1277-1288.
173. Dejean,A. et al. (1986) Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature, 322, 70-72.
174. Garcia,M. et al. (1993) A hepatitis B virus pre-S-retinoic acid receptor beta chimera transforms erythrocytic progenitor cells in vitro. Proc. Natl Acad. Sci. USA, 90, 89-93.
175. Zhang,X.K. et al. (1992) Hepatitis B virus DNA integration and expression of an erb B-like gene in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun., 188, 344-351.
176. Graef,E. et al. (1994) Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene, 9, 81-87.
177. Graef,E. et al. (1995) Enzymatic properties of overexpressed HBVmevalonate kinase fusion proteins and mevalonate kinase proteins in the human hepatoma cell line PLC/PRF/5. Virology, 208, 696-703.
178. Pineau,P. et al. (1996) A t(3;8) chromosomal translocation associated with hepatitis B virus intergration involves the carboxypeptidase N locus. J. Virol., 70, 7280-7284.
179. Horikawa,I. et al. (2001) cis-Activation of the human telomerase gene (hTERT) by the hepatitis B virus genome. J. Natl Cancer Inst., 93, 1171-1173.
180. Horikawa,I. et al. (2003) Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis, 24, 1167-1176.
181. Hytiroglou,P. et al. (2006) Telomerase activation in human hepatocarcinogenesis. Am. J. Gastroenterol., 101, 839-841.
182. Su,Q. et al. (1998) Expression of hepatitis B virus X protein in HBVinfected human livers and hepatocellular carcinomas. Hepatology, 27, 1109-1120.
183. Poussin,K. et al. (1999) Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int. J. Cancer, 80, 497-505.
184. Tamori,A. et al. (1999) Possible contribution to hepatocarcinogenesis of X transcript of hepatitis B virus in Japanese patients with hepatitis C virus. Hepatology, 29, 1429-1434.
185. Su,Q. et al. (2000) Overexpression of p53 protein is not directly related to hepatitis B x protein expression and is associated with neoplastic progression in hepatocellular carcinomas rather than hepatic preneoplasia. Mutat. Res., 462, 365-380.
186. Yotsuyanagi,H. et al. (2002) Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J. Hepatol., 37, 355-363.
187. León,B. et al. (2005) HBx M130K and V131I (T-A) mutations in HBV genotype F during a follow-up study in chronic carriers. Virol. J., 2, 60.
188. Kim,C.M. et al. (1991) HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature, 351, 317-320.
189. Ullrich,S.J. et al. (1994) Transgenic mouse models of human gastric and hepatic carcinomas. Semin. Cancer Biol., 5, 61-68.
190. Koike,K. et al. (1994) High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology, 19, 810-819.
191. Koike,K. (1995) Hepatitis B virus HBx gene and hepatocarcinogenesis. Intervirology, 38, 134-142.
192. Billet,O. et al. (1995) In vivo activity of the hepatitis B virus core promoter: tissue specificity and temporal regulation. J. Virol., 69, 5912-5916.
193. Slagle,B.L. et al. (1996) Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol. Carcinog., 15, 261-269.
194. Terradillos,O. et al. (1997) The hepatitis B virus X gene potentiates cmyc-induced liver oncogenesis in transgenic mice. Oncogene, 14, 395-404.
195. Lucito,R. et al. (1992) Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J. Virol., 66, 983-991.
196. Cross,J.C. et al. (1993) Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc. Natl Acad.Sci. USA, 90, 8078-8082.
197. Natoli,G. et al. (1994) Induction of the DNA-binding activity of c-jun/cfos heterodimers by the hepatitis B virus transactivator pX. Mol. Cell. Biol., 14, 989-998.
198. Cheong,J.H. et al. (1995) Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J., 14, 143-150.
199. Williams,J.S. et al. (1995) The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB. Proc. Natl Acad. Sci. USA, 92, 3819-3823.
200. Benn,J. et al. (1994) Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl Acad. Sci. USA, 91, 10350-10354.
201. Benn,J. et al. (1996) Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J. Virol., 70, 4978-4985.
202. Lee,Y.H. et al. (1998) HBx protein of hepatitis B virus activates Jak1-STAT signaling. J. Biol. Chem., 273, 25510-25515.
203. Lee,Y.I. et al. (2001) The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem., 276, 16969-16977.
204. Wang,W.H. et al. (2011) Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication. Hepatology, 53, 1137-1147.
205. Tang,H. et al. (2006) Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci., 97, 977-983.
206. Kew,M.C. (2011) Hepatitis B virus x protein in the pathogenesis of hepatitis B virus-induced hepatocellular carcinoma. J. Gastroenterol. Hepatol, 26 (suppl. 1):144-152.
207. Feitelson,M.A. et al. (1993) Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene, 8, 1109-1117.
208. Wang,X.W. et al. (1994) Hepatitis B virus X protein inhibits p53 sequencespecific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA, 91, 2230-2234.
209. Ueda,H. et al. (1995) Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet., 9, 41-47.
210. Wang,X.W. et al. (1995) Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res., 55, 6012-6016.
211. Takada,S. et al. (1997) Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene, 15, 1895-1901.
212. Ahn,J.Y. et al. (2002) Dual effects of hepatitis B virus X protein on the regulation of cell-cycle control depending on the status of cellular p53. J. Gen. Virol., 83, 2765-2772.
213. Mathonnet,G. et al. (2004) Expression of hepatitis B virus X oncoprotein inhibits transcription-coupled nucleotide excision repair in human cells. Mutat. Res., 554, 305-318.
214. Hussain,S.P. et al. (2007) TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene, 26, 2166-2176.
215. Henkler,F. et al. (1995) Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus-related human hepatocellular carcinoma. Cancer Res., 55, 6084-6091.
216. Terradillos,O. et al. (2002) The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene, 21, 377-386.
217. Chami,M. et al. (2003) Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein. J. Biol. Chem., 278, 31745-31755.
218. Zhang,J.L. et al. (2005) Human hepatitis B virus X protein promotes cell proliferation and inhibits cell apoptosis through interacting with a serine protease Hepsin. Arch. Virol., 150, 721-741.
219. Li,D. et al. (2003) The inhibition of apoptosis of hepatoma cells induced by HBx is mediated by up-regulation of survivin expression. J. Huazhong Univ. Sci. Technolog. Med. Sci., 23, 383-386.
220. Terradillos,O. et al. (1998) p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene, 17, 2115-2123.
221. Shin,E.C. et al. (1999) Expression of fas ligand in human hepatoma cell lines: role of hepatitis-B virus X (HBX) in induction of Fas ligand. Int. J. Cancer, 82, 587-591.
222. Lee,M.O. et al. (2002) Hepatitis B virus X protein induced expression of interleukin 18 (IL-18): a potential mechanism for liver injury caused by hepatitis B virus (HBV) infection. J. Hepatol., 37, 380-386.
223. Yoo,Y.G. et al. (2004) Hepatitis B virus X protein induces expression of Fas ligand gene through enhancing transcriptional activity of early growth response factor. J. Biol. Chem., 279, 36242-36249.
224. Kim,K.H. et al. (2003) Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J., 22, 2104-2116.
225. Miao,J. et al. (2006) Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression. Cancer Lett., 236, 115-124.
226. Lee,S.W. et al. (2000) Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem. Biophys. Res. Commun., 268, 456-461.
227. Yoo,Y.G. et al. (2004) The carboxy-terminus of the hepatitis B virus X protein is necessary and sufficient for the activation of hypoxia-inducible factor-1alpha. FEBS Lett., 577, 121-126.
228. Moon,E.J. et al. (2004) Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J., 18, 382-384.
229. Belloni,L. et al. (2009) Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl Acad. Sci. USA, 106, 19975-19979.
230. Lee,J.O. et al. (2005) Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene, 24, 6617-6625.
231. Liu,J. et al. (2006) Downregulation of E-cadherin by hepatitis B virus X antigen in hepatocellullar carcinoma. Oncogene, 25, 1008-1017.
232. Park,I.Y. et al. (2007) Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology, 132, 1476-1494.
233. Jung,J.K. et al. (2007) Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res., 67, 5771-5778.
234. Zheng,D.L. et al. (2009) Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J. Hepatol., 50, 377-387.
235. Huang,J. et al. (2010) Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology, 52, 60-70.
236. Schlüter,V. et al. (1994) Integrated hepatitis B virus X and 3' truncated preS/S sequences derived from human hepatomas encode functionally active transactivators. Oncogene, 9, 3335-3344.
237. Deodhar,K.P. et al. (1975) Orcein staining of hepatitis B antigen in paraffin sections of liver biopsies. J. Clin. Pathol., 28, 66-70.
238. Winckler,K. et al. (1976) Ground-glass hepatocytes in unselected liver biopsies. ultrastructure and relationship to hepatitis B surface antigen. Scand. J. Gastroenterol., 11, 167-170.
239. Amat,D. et al. (1981) Hepatocyte localization of hepatitis B core and surface antigens in renal transplant recipients. An ultrastructural prospective study. Virchows Arch. A Pathol. Anat. Histol., 391, 153-163.
240. Su,I.J. et al. (2008) Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J. Gastroenterol. Hepatol., 23, 1169-1174.
241. Raimondo,G. et al. (2004) Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J. Hepatol., 40, 515-519.
242. Chemin,I. et al. (1999) Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver, 19, 81-87.
243. Hung,J.H. et al. (2004) Endoplasmic reticulum stress stimulates the expression of cyclooxygenase-2 through activation of NF-kappaB and pp.38 mitogen-activated protein kinase. J. Biol. Chem., 279, 46384-46392.
244. Marchio,A. et al. (2000) Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene, 19, 3733-3738.
245. Laurent-Puig,P. et al. (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 120, 1763-1773.
246. Lin,Y.W. et al. (1999) Chromosomal abnormality in hepatocellular carcinoma by comparative genomic hybridisation in Taiwan. Eur. J. Cancer, 35, 652-658.
247. Zondervan,P.E. et al. (2000) Molecular cytogenetic evaluation of virusassociated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias. J. Pathol., 192, 207-215.
248. Kusano,N. et al. (2002) Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer, 94, 746-751.
249. Katoh,H. et al. (2005) Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J. Hepatol., 43, 863-874.
250. Moinzadeh,P. et al. (2005) Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Br. J. Cancer, 92, 935-941.
251. Sy,S.M. et al. (2005) Regional over-representations on chromosomes 1q, 3q and 7q in the progression of hepatitis B virus-related hepatocellular carcinoma. Mod. Pathol., 18, 686-692.
252. Poon,T.C. et al. (2006) A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. Gastroenterology, 131, 1262-1270.
253. Tsai,W.L. et al. (2010) Viral hepatocarcinogenesis. Oncogene, 29, 2309-2324.
254. Boyault,S. et al. (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 45, 42-52.
255. Ura,S. et al. (2009) Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology, 49, 1098-1112.
256. Woo,H.G. et al. (2008) Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res., 14, 2056-2064.
257. Hoshida,Y. et al. (2009) Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res., 69, 7385-7392.
258. Saito,Y. et al. (2001) Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology, 33, 561-568.
259. Choi,M.S. et al. (2003) Expression of DNA methyltransferases in multistep hepatocarcinogenesis. Hum. Pathol., 34, 11-17.
260. Saito,Y. et al. (2003) Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int. J. Cancer, 105, 527-532.
261. Zhong,S. et al. (2002) Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carcinomas. Clin. Cancer Res., 8, 1087-1092.
262. Zhang,Y.J. et al. (2007) Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin. Cancer Res., 13, 2378-2384.
263. Zhu,Y.Z. et al. (2010) Hepatitis B virus X protein promotes hypermethylation of p16(INK4A) promoter through upregulation of DNA methyltransferases in hepatocarcinogenesis. Exp. Mol. Pathol., 89, 268-275.
264. Vivekanandan,P. et al. (2010) Hepatitis B virus replication induces methylation of both host and viral DNA. J. Virol., 84, 4321-4329.